Retatrutide Weight Loss Truth
Dr. Brad Stanfield — Retatrutide Weight Loss Truth
Channel: Dr Brad Stanfield · Our label: Physician educator — skeptical, evidence-first voice · Source: youtube.com/watch?v=w0A_VRT3rIE
What this video covers
A freshly published study demonstrated a whopping 28.7% weight loss over a 68-week time period from a drug called Retatrutide. Plus, it brought profound relief from pain caused by knee arthritis. But the very first thought that should go off in our minds is what’s the downside? So, let’s have a look at the results and see how this new treatment compares to what’s already on the market.
Summary drawn from this video’s own transcript (banked in our research library, pulled 2026-11-07). Claims below are the speaker’s — attributed, not endorsed. This site publishes no dosing, protocol, or sourcing information.
Key points, in the speaker’s own framing
- A freshly published study demonstrated a whopping 28.7% weight loss over a 68-week time period from a drug called Retatrutide.
- So, the first is glucagon-like peptide 1 or GLP-1.
- So, we know a lot about that peptide and the most famous drug that only contains that peptide is ampic.
- But GLP-1 medications have been used in clinical medicine to treat type 2 diabetes since 2005.
- And the big innovation with GLP-1 medications was figuring out how to stop GLP-1 from being broken down so quickly.
- So, in the two studies of toepide, for instance, 0.4% of participants reported that side effect, but in this new retride study, almost 21% of those at the highest doses reported disesthesia and the figure was 7% with placebo.
Read next
Educational information only — not medical advice. Peptides discussed on this page include substances that are not FDA-approved.